| 21. |
- Hollestelle, Antoinette, et al.
(author)
-
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
- 2016
-
In: Gynecologic Oncology. - : Elsevier BV. - 0090-8258 .- 1095-6859. ; 141:2, s. 386-401
-
Journal article (peer-reviewed)abstract
- Objective Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3′ UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370. Methods Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation carriers). Results We found no association with risk of ovarian cancer (OR = 0.99, 95% CI 0.94-1.04, p = 0.74) or breast cancer (OR = 0.98, 95% CI 0.94-1.01, p = 0.19) and results were consistent among mutation carriers (BRCA1, ovarian cancer HR = 1.09, 95% CI 0.97-1.23, p = 0.14, breast cancer HR = 1.04, 95% CI 0.97-1.12, p = 0.27; BRCA2, ovarian cancer HR = 0.89, 95% CI 0.71-1.13, p = 0.34, breast cancer HR = 1.06, 95% CI 0.94-1.19, p = 0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR = 0.94, 95% CI 0.83-1.07, p = 0.38), breast cancer (HR = 0.96, 95% CI 0.87-1.06, p = 0.38), and all other previously-reported associations. Conclusions rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers.
|
|
| 26. |
- Lerche, E., et al.
(author)
-
Optimization of ICRH for core impurity control in JET-ILW
- 2016
-
In: Nuclear Fusion. - JET, Culham Sci Ctr, EUROfus Consortium, Abingdon OX14 3DB, Oxon, England. [Lerche, E.; Van Eester, D.; Crombe, K.; Kazakov, Y.; Krivska, A.; Ongena, J.] TEC Partner, Assoc EUROFUS Belgian State, LPP ERM KMS, Brussels, Belgium. [Lerche, E.; Jacquet, P.; Giroud, C.; Monakhov, I.; Casson, F. J.; Rimini, F.; Blackman, T.; Brix, M.; Challis, C.; Graham, M.; Kiptily, V.; Lennholm, M.; Lomas, P.; Maggi, C.; Mathews, G.; Mayoral, M. -L.; Santala, M.; Shaw, A.; Stamp, M.] Euratom CCFE Fus Assoc, Culham Sci Ctr, Abingdon, Oxon, England. [Goniche, M.; Colas, L.; Fedorczak, N.; Joffrin, E.; Monier-Garbet, P.] Assoc EUROFUS CEA, IRFM, St Paul Les Durance, France. [Bobkov, V.; Angioni, C.; Hobirk, J.; Puetterich, T.; Reich, M.] EUROFUS Assoziat, Max Planck Inst Plasmaphys, Garching, Germany. [Baruzzo, M.] EUROFUS ENEA Assoc, Consorzio RFX, Padua, Italy. [Brezinsek, S.] TEC Partner, EUROFUS Assoziat, Forschungszentrum Juelich, Julich, Germany. [Czarnecka, A.] EUROFUS Assoc, IPPLM, Warsaw, Poland. [Eriksson, J.] Uppsala Univ, Dept Phys & Astron, Assoc EUROFUS VR, Uppsala, Sweden. [Graves, J. P.] Assoc EUROFUS Confederat Suisse, CRPP EPFL, Lausanne, Switzerland. [Gorini, G.; Mantica, P.; Nocente, M.; Tardocchi, M.; Valisa, M.] EUROFUS ENEA CNR Assoc, Inst Fis Plasma, Milan, Italy. [Johnson, T.] KTH, EES, Fus Plasma Phys, Assoc EUROFUS VR, Stockholm, Sweden. [Meneses, L.; Nave, M. F.; Nunes, I.] EUROFUS IST Assoc, Inst Plasmas & Fusao Nucl, Lisbon, Portugal. [Mlynar, J.; Petrzilka, V.] EUROFUS IPP CR Assoc, Inst Plasma Phys, Prague, Czech Republic. [Petravich, G.] EUROFUS Assoc, MTA Wigner FK RMI, Budapest, Hungary. [Solano, E. R.] EUROFUS Assoc, LNF CIEMAT, Madrid, Spain. [Solano, E. R.] Culham Sci Ctr, EUROfus PMU, Abingdon OX14 3DB, Oxon, England. [Sips, G.] Culham Sci Ctr, JET Exploitat Unit, Abingdon OX14 3DB, Oxon, England. [Tsalas, M.] EUROFUS Assoc, FOM Inst DIFFER, Nieuwegein, Netherlands. : Institute of Physics (IOP). - 0029-5515 .- 1741-4326. ; 56:3
-
Journal article (peer-reviewed)abstract
- Ion cyclotron resonance frequency (ICRF) heating has been an essential component in the development of high power H-mode scenarios in the Jet European Torus ITER-like wall (JET-ILW). The ICRF performance was improved by enhancing the antenna-plasma coupling with dedicated main chamber gas injection, including the preliminary minimization of RF-induced plasma-wall interactions, while the RF heating scenarios where optimized for core impurity screening in terms of the ion cyclotron resonance position and the minority hydrogen concentration. The impact of ICRF heating on core impurity content in a variety of 2.5 MA JET-ILW H-mode plasmas will be presented, and the steps that were taken for optimizing ICRF heating in these experiments will be reviewed.
|
|
